Immune correlates in melanoma sentinel lymph node metastases

See page1535
Kakavand and colleagues characterized the immune environment of sentinel lymph nodes from patients with early-stage melanoma. These patients have variable 5-year survival rates of 39-70%, predicted to some degree by tumor burden and number of lymph nodes involved. The effects of local antitumor response and the potential applicability of immune checkpoint inhibitors in this early setting are unknown. Checkpoint inhibitors can show remarkable efficacy in patients with unresectable late-stage metastatic melanoma. Significant positive correlation with recurrence-free and overall survival was seen with the numbers of CD3 + , CD4 + , and CD8 + tumorinfiltrating lymphocytes. Negative correlations were seen with the number of peritumoral PD-1 + lymphocytes. Tumoral PD-L1 expression was noted in 43% of cases but lacked correlation with outcome. This study suggests prognostic significance of lymphocytic infiltrates in melanoma sentinel lymph node metastases and indicates that adjuvant checkpoint inhibitor therapy may be considered in patients with early-stage metastatic disease.
Telomeres and ATRX expression in sarcoma
See page 1545
On the basis of their cytogenetic profiles, sarcomas can be broadly characterized as either simple (often bearing recurrent chromosomal translocation) or complex karyotype tumors. Alternative lengthening of telomeres (ALT), a common method of telomere maintenance in sarcoma, is often associated with loss of ATRX or DAXX protein. Liau et al found that that ALT is very common in complex karyotype sarcoma, such as undifferentiated pleomorphic sarcoma (UPS; 65%) and myxofibrosarcoma (MFS; 76%), but ATRX (or DAXX) loss was seen in half of the UPS cases with ALT and only one of the MFS cases with ALT. Clearly other mechanisms exist. Although often not of the complex karyotype, dedifferentiated liposarcomas commonly show ALT (45%); this is explained mostly by ATRX loss (93%). ALT and ATRX loss was seen in only a few cases of the translocation sarcomas tested as well as in gastrointestinal stromal tumors and epithelioid sarcoma.
G-CSF limits neural tissue damage after spinal cord injury
See page 1439
Using a mouse spinal cord hemisection model, Guo et al studied the effects of granulocyte colony-stimulating factor (G-CSF). Neural damage is associated with a progressive cascade of secondary injuries associated with apoptosis. G-CSF is known to inhibit apoptosis in neutrophils, and its receptor is also expressed in central nervous system cells. There is emerging evidence that G-CSF may have neuroprotective effects. The authors' results suggest that the presence of G-CSF promotes autophagy after spinal neuronal injury at the expense of the apoptosis and thus decreases the extent of local damage. When autophagy is inhibited during G-CSF exposure, apoptosis increases with associated increased spinal injury. The mechanism for this appears to be G-CSF-mediated inhibition of the nuclear factor-κB pathway. This increase in autophagy in response to G-CSF is rapid, and activation of the pathway may have therapeutic applications.
Jejunal lipogenesis in morbid obesity with insulin resistance
See page 1409
Type 2 diabetes is often associated with dyslipidemia, an important risk factor for atherosclerosis. 
Genomics of breast fibroepithelial neoplasia
Breast fibroepithelial neoplasia ranges from benign fibroadenomas to phyllodes to borderline and malignant phyllodes tumors. As recently described in Nature Genetics, Tan et al confirmed the previously demonstrated MED12 mutations in both fibroadenomas (n = 100, targeted sequencing) and phyllodes tumors (n = 22 exomes). RARA mutations were common in both groups and coexistent with MED12 mutations rather than mutually exclusive. The RARA mutations clustered in the encoded ligand binding domain and functionally suppressed RARA-mediated transcriptional activation, probably by enhancing RARA interactions with transcriptional corepressors. MED12 and RARA mutations appeared to facilitate fibroepithelial tumorigenesis. Phyllodes tumors of all types-benign, borderline, and malignant-had additional mutations in FLNA, SETD2, and KMT2D. For the borderline and malignant phyllodes tumors, mutations in more classic proto-oncogenes and tumor suppressors such as PIK3CA, EGFR, NF1, RB1 and TP53 were noted. These results suggest molecular progression across the tumor spectrum and may have therapeutic implications.
Nature Genetics, published online 5 October 2015; doi:10.1038/ng.3409*
Intron retention in tumor suppressor inactivation
Loss of tumor-suppressor-gene expression is important in many cancers. Jung et al, in a study reported in Nature Genetics, examined the mechanisms of this loss. They noted that substantial numbers of mutations in cancer result from aberrant splicing. Somatic single-nucleotide variants (SNVs) have been well characterized in cancer exomes, but their association with abnormal RNA splicing is relatively unexplored. Through coordinated examination of exome and RNA sequencing data across more than 1,800 cancer cases, the authors identified ~900 exonic SNVs that disrupt splicing. No fewer than 163 SNVs-interestingly, including 31 synonymous substitutions-were shown to result in either intron retention or exon skipping in an allele-specific fashion. Approximately 70% of these SNVs occurred at the last base of exons, adjacent to the splice site. The vast majority of the retained introns led to a premature termination codon, resulting in nonsense-related decay or predicted protein truncation. This study has clear implications for molecular diagnostics. 
